Journal Mobile Options
Table of Contents
Vol. 21, No. 1, 2006
Issue release date: December 2005
Fetal Diagn Ther 2006;21:84–91
(DOI:10.1159/000089055)

Increased Expression of Vascular Endothelial Growth Factor in Cardiac Structures of Fetus with Hydrops as Compared to Nonhydropic Controls

Brandenburg H. · Bartelings M.M. · Wisse L.J. · Steegers E.A.P. · Gittenberger-de Groot A.C.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: The hypothesis that severe fetal hydrops is caused by an excess of vascular endothelial growth factor (VEGF), mainly produced in the fetal heart, is tested. Methods: Immunohistochemical VEGF-stained postmortem biopsies from the right ventricle and right atrium of 8 hydropic fetuses were compared to those of 8 nonhydropic fetuses. The endocardium, myocardium, epicardium, endothelium, and vascular smooth muscle cells were scored on intensity of VEGF-staining. The Mann-Witney test was used to test for significancy (p < 0.05) of the differences in staining. Increased vascularization as a result of VEGF was measured in both groups by standard randomization count. Results: The endocardium, epicardium and endothelium of the coronary vessels showed significantly (p < 0.05) more intense VEGF-staining in the hydrops group than in the control group. The atria showed more intense staining than the ventricles in both groups. The hydropic fetuses showed a significantly increased number of coronary vessels in the myocardium. These vessels contained more blood cells than the coronary vessels in nonhydropic fetuses. Conclusion: The fetal heart appears to be a major source of excess VEGF in fetal hydrops.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Knilans TK: Cardiac abnormalities associated with hydrops fetalis. Semin Perinatol 1995;19:483–492.
  2. Gembruch U, Hansmann M, Bald R, Zerres K, Schwanitz G, Fodisch HJ: Prenatal diagnosis and management in fetuses with cystic hygromata colli. Eur J Obstet Gynecol Reprod Biol 1988;29:241–255.
  3. Droste S, Hendrickx SK, Von Alfrey H, Mack LA: Cystic hygroma colli: perinatal outcome after prenatal diagnosis. J Perinat Med 1991;19:449–454.
  4. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309–1312.
  5. Ladoux A, Frelin C: Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. Biochem Biophys Res Commun 1993;195:1005–1010.
  6. Sasaki H, Fukudaa S, Otani H, Zhu L, Yamauraa G, Engelman RM, Das DK, Maulik N: Hypoxic preconditioning triggers myocardial angiogenesis: a novel approach to enhance contractile functional reserve in rat with myocardial infarction. J Mol Cell Cardiol 2002;34:335–348.
  7. Gruden G, Thomas S, Burt D, Lane S, Chusney G, Sacks S, Viberti G: Mechanical stretch induces vascular permeability factor in human mesangial cells: mechanisms of signal transduction. Proc Natl Acad Sci USA 1997;94:12112–12116.
  8. Lantieri LA, Martin-Garcia N, Wechsler J, Mitrofanoff M, Raulo Y, Baruch JP: Vascular endothelial growth factor expression in expanded tissue: a possible mechanism of angiogenesis in tissue expansion. Plast Reconstr Surg 1998;101:392–398.
  9. Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sorensen FB, Vesterby A, West MJ: Some new, simple and efficient stereological methods and the use in pathological research and diagnosis. APMIS 1988;96:379–394.
  10. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003;9:669–676.
  11. Shibuya M: VEGF-receptor inhibitors for anti-angiogenesis. Nippon Yakurigaku Zasshi 2003;122:498–503.
  12. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor-1. Mol Cell Biol 1996;16:4604–4613.
  13. Pedram A, Razandi M, Hu RM, Levin ER: Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 1997;272:17097–17103.
  14. Sternberg SS (ed): Histology for Pathologists, ed 2. Philadelphia, Lippincott-Raven, 2000, p 748.
  15. Ruck A, Gustafsson T, Norrbom J, Nowak J, Kallner G, Sodert M, Sylven C, Drvota V: ANP and BNP but not VEGF are regionally overexpressed in ischemic human myocardium. Biochem Biophys Res Commun 2004;322;287–291.
  16. Pedram A, Razandi M, Levin ER: Natriuretic peptides suppress vascular endothelial cell growth factor signaling to angiogenesis. Endocrinology 2001;142:1578–1586.
  17. Pedram A, Razandi M, Levin ER: Deciphering vascular endothelial cell growth factor/vascular permeability factor signaling to vascular permeability. Inhibition by atrial natriuretic peptide. J Biol Chem 2002;277:44385–44398.
  18. Cheung CY: Vascular endothelial growth factor: possible role in fetal development and placental function. J Soc Gynecol Investig 1997;4:169–177.
  19. Faller DV: Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 1999;26:74–84.
  20. Ottino P, Finley J, Rojo E, Ottlecz A, Lambrou GN, Bazan HE, Bazan NG: Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: involvement of cytosolic phospholipase A2 activity. Mol Vis 2004;10:341–350.
  21. Blair DK, Vanderstraten MC, Gest AL: Hydrops in fetal sheep from rapid induction of anaemia. Pedatr Res 1994;35:560–564.
  22. Davis LE, Hohimer AR, Giraud GD, Reller MD, Morton MJ: Right ventricular function in chronically anemic lambs. Am J Obstet Gynecol 1996;174:1289–1294.
  23. Tordjman R, Delaire S, Plouët J, Ting S, Gaulard P, Fichelson S, Roméo PH, Lemarchandel V: Erythroblasts are a source of angiogenic factors. Blood 2001;97:1968–1974.
  24. Newbold MJ, Armstrong GR, Barson AJ: Endocardial fibroelastosis in infants with hydrops fetalis. J Clin Pathol 1991;44:576–579.
  25. Silver MD (ed): Cardiovascular Pathology, ed 2. New York, Churchill Livingstone, 1991, p 780.
  26. Le YJ, Corry PM: Hypoxia-induced bFGF gene expression is mediated through JNK signal transduction pathway. Mol Cell Biochem 1999;202:1–8.
  27. Wolfson DJ, Pepkowitz SH, van de Velde R, Fishbein MC: Primary endocardial fibroelastosis associated with hydrops fetalis in a premature infant. Am Heart J 1990;120:708–711.
  28. Carvalho JS, Markiewitz M: Dilated endocardial fibroelastosis: unusual late finding with congenital hydrops. Pediatr Cardiol 1997;18:389–391.
  29. van Kamp IL, Klumper FJ, Bakkum RS, Oepkes D, Meerman RH, Scherjon SA, Kanhai HH: The severity of immune hydrops is predictive of fetal outcome after intrauterine treatment. Am J Obstet Gynecol 2001;185:668–673.
  30. Zosmer N, Bajoria R, Weiner E, Rigby M, Vaughan J, Fisk NM: Clinical and echographic features of in utero cardiac dysfunction in the recipient twin in twin-twin transfusion syndrome. Br Heart J 1994;72:74–79.
  31. Simpson LL, Marx GR, Elkadry EA, D’Alton ME: Cardiac dysfunction in twin-twin transfusion syndrome: a prospective, longitudinal study. Obstet Gynecol 1998;92:557–562.
  32. Dor Y, Camenissch TD, Itin A, Fishman GI, McDonald JA, Carmeliet P, Keshet E: A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects. Development 2001;128:1531–1538.
  33. Brandenburg H, de Krijger RR, Visser W, Wessels MW, Steegers EA: Maternal complications in fetal hydrops. Ned Tijdschr Geneeskd 2002;146:2367–2370.
  34. Shiraishi S, Kinukawa N, Nakano H, Sueishi K: Immunohistochemical distribution of vascular endothelial growth factor in the human placenta associated with hydrops fetalis. Pediatr Pathol Lab Med 1997;17:65–81.
  35. Deurloo K, Devlieger R, Oepkes D: Maternal hydrops syndrome following successful treatment of fetal hydrops by shunting of bilateral hydrothorax. Prenat Diagn 2003;23:944–945.
  36. Nauck M, Karakiulakis G, Perruchaod AP, Papakonstantinou E, Roth M: Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;34:309–315.
  37. Tsai JC, Hsiao YY, Teng LJ, Shun CT, Chen CT, Goldman CK, Kao MC: Regulation of vascular endothelial growth factor secretion in human meningioma cells. J Formos Med Assoc 1999;98:111–117.
  38. Tsao K, Hawgood S, Vu L, Hirose S, Sydorak R, Albanese CT, Farm DL, Harrison MR, Lee H: Resolution of hydrops fetalis in congenital cystic adenomatoid malformation after prenatal steroid therapy. J Pediatr Surg 2003;38:508–510.
  39. Yamada H, Kato EH, Ebina Y, Moriwaki M, Yamamoto R, Furuta I, Fujimoto S: Fetal treatment of congenital heart block ascribed to anti-SSA antibody: case reports with observation of cardiohemodynamics and review of the literature. Am J Reprod Immunol 1999;42:226–232.
  40. Chua S, Ostman-Smith I, Sellers S, Redman CW: Congenital heart block with hydrops fetalis treated with high dose dexamethasone: a case report. Eur J Obstet Gynecol Reprod Biol 1991;42:155–158.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50